Our preliminary conclusion is that CKI could be used for GC therapy by activating signaling pathways such as PI3K/AKT, MAPK, ABC transporter and ECM-receptor interaction pathways to inhibit cancer cell proliferation and regulate immunity. The gene discussed is ABCG2; the disease is gastric cancer.